Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy - Takeaways - MDSpire

Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy

  • By

  • Zhiyong Liu

  • Jianhe Wu

  • Qiang Lu

  • Yuanwei Li

  • Yongjun Yang

  • June 24, 2026

  • 0 min

Share

  • 1

    Prostate cancer diagnosis is shifting from invasive procedures to precision, minimally invasive, and non-invasive approaches.

  • 2

    Multiparametric magnetic resonance imaging (mpMRI) enhances patient selection for biopsy, increasing detection rates of clinically significant prostate cancer.

  • 3

    Transperineal biopsy is emerging as the new standard due to its reduced risk of infection compared to transrectal biopsy.

  • 4

    Biopsy strategies are evolving from systematic to targeted, utilizing advanced imaging modalities for individualized patient care.

  • 5

    The article proposes a structured clinical pathway for a 'biopsy-free diagnosis' paradigm based on advanced imaging and molecular biomarkers.

Original Source(s)

Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy

  • by Zhiyong Liu, Jianhe Wu, Qiang Lu, Yuanwei Li, Yongjun Yang

  • June 24, 2026

Related Content

Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials: A Systematic

Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies

Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study